## Prescriber Criteria Form

## Octreotide 2025 PA Fax 4361-A v1 010125.docx Sandostatin (octreotide acetate injection) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact

CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Sandostatin (octreotide acetate injection).

Drug Name: Sandostatin (octreotide acetate injection)

| Patient Name:       |                 |          |  |
|---------------------|-----------------|----------|--|
| Patient ID:         |                 |          |  |
| Patient DOB:        | Patient Phone:  |          |  |
| Prescriber Name:    | <u> </u>        |          |  |
| Prescriber Address: |                 |          |  |
| City:               | State:          | Zip:     |  |
| Prescriber Phone:   | Prescriber Fax: | <u> </u> |  |
| Diagnosis:          | ICD Code(s):    |          |  |

| 1 | Does the patient have a diagnosis of acromegaly?  | Yes | No |
|---|---|-----|----|
|   | [If no, then skip to question 6.]   |     |    |
| 2 | Is the patient currently receiving therapy with the requested drug? [If no, then skip to question 4.]   | Yes | No |
| 3 | Has the patient's insulin-like growth factor-1 (IGF-1) level decreased or normalized since initiation of therapy?  [No further questions.]  | Yes | No |
| 4 | Does the patient have a high pre-treatment insulin-like growth factor-1 (IGF-1) level for age and/or gender based on the laboratory reference range? [If no, then no further questions.]  | Yes | No |
| 5 | Does the patient meet any of the following criteria: A) the patient had an inadequate or partial response to surgery or radiotherapy, B) there is a clinical reason for why the patient has not had surgery or radiotherapy?  [No further questions.]                         | Yes | No |
| 6 | Is the requested drug prescribed for any of the following: A) treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor, B) treatment of profuse watery diarrhea associated with a vasoactive intestinal peptide tumor (VIPoma)-secreting | Yes | No |

|         | tumor? [If yes, then no further questions.]   |         |    |
|---------|---|---------|----|
| 7       | Is the requested drug being prescribed for tumor control of a thymoma or thymic carcinoma?  | Yes     | No |
| Comme   | nts:  |         |    |
|         | ng this form, I attest that the information provided is accurate and true as of this date and to ntation supporting this information is available for review if requested by the health plan. | nat the |    |
| Prescri | ber (or Authorized) Signature: Date:  |         |    |